319 related articles for article (PubMed ID: 35608658)
1. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
[TBL] [Abstract][Full Text] [Related]
2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
3. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
Filippi M; Danesi R; Derfuss T; Duddy M; Gallo P; Gold R; Havrdová EK; Kornek B; Saccà F; Tintoré M; Weber J; Trojano M
J Neurol; 2022 Mar; 269(3):1670-1677. PubMed ID: 34626224
[TBL] [Abstract][Full Text] [Related]
4. Identification and management of subclinical disease activity in early multiple sclerosis: a review.
Ontaneda D; Chitnis T; Rammohan K; Obeidat AZ
J Neurol; 2024 Apr; 271(4):1497-1514. PubMed ID: 37864717
[TBL] [Abstract][Full Text] [Related]
5. Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G; Arun T; Capela C; Laureys G; Jones E; Dominguez-Castro P; Sanchez-de la Rosa R; Hiltl S; Iaffaldano P
Mult Scler Relat Disord; 2023 Aug; 76():104770. PubMed ID: 37307690
[TBL] [Abstract][Full Text] [Related]
6. The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study.
Fuh-Ngwa V; Charlesworth JC; Zhou Y; van der Mei I; Melton PE; Broadley SA; Ponsonby AL; Simpson-Yap S; Lechner-Scott J; Taylor BV
Sci Rep; 2023 Jul; 13(1):11584. PubMed ID: 37463930
[TBL] [Abstract][Full Text] [Related]
7. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
10. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
11. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021.
Stastna D; Drahota J; Lauer M; Mazouchova A; Menkyova I; Adamkova J; Ampapa R; Dufek M; Grunermelova M; Hradilek P; Kubala Havrdova E; Mares J; Martinkova A; Pavelek Z; Peterka M; Recmanova E; Rockova P; Stetkarova I; Stourac P; Vachova M; Horakova D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Apr; ():. PubMed ID: 37114703
[TBL] [Abstract][Full Text] [Related]
12. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
13. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
Singer BA; Feng J; Chiong-Rivero H
J Neurol; 2024 Jun; 271(6):3116-3130. PubMed ID: 38615277
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Treatment of Multiple Sclerosis: A Review.
McGinley MP; Goldschmidt CH; Rae-Grant AD
JAMA; 2021 Feb; 325(8):765-779. PubMed ID: 33620411
[TBL] [Abstract][Full Text] [Related]
18. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
19. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
[TBL] [Abstract][Full Text] [Related]
20. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
